Page 6 - உலகளாவிய கூட்டணி க்கு மாற்றி அமைக்கத்தக்க ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Posted on
288
Global Coalition for Adaptive Research (LOS ANGELES, CA), Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA, SYDNEY, Australia), and Kintara Therapeutics, Inc. (NASDAQ: KTRA, SAN DIEGO, CA) The Global Coalition for Adaptive Research (GCAR) in collaboration with Kazia and Kintara, today announced the activation of Kazia’s
paxalisib and Kintara’s
VAL-083 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.
Kazia’s
paxalisib and Kintara’s
VAL-083 are entering the GBM AGILE trial, which initially opened in July 2019 and has screened over 370 patients to date. ....

United States , New South Wales , San Diego , James Perry , James Garner , Eudociaq Lee , Ingo Mellinghoff , Jules Abraham , Tom Mikkelsen , Rachel Rosenstein Sisson , Global Coalition For Adaptive Research , Kintara Therapeutics Inc , Md Anderson Cancer Center , Department Of Neuro , University Of Toronto , Kazia Therapeutics Limited , National Brain Tumor Society , Clinical Research , Kazia Therapeutics , Selection Committee , Us National Cancer Institute , Sunnybrook Research Institute , Harvard Medical School , National Foundation For Cancer Research , Asian Fund For Cancer Research , Henry Ford Precision Medicine Program Clinical Trials ,